NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN) is engaged as a clinical-stage biotechnology company, which is focused on the research and development of treatments for neurodegenerative diseases. Shares of the biotech company are soaring 292% through early trading on Monday, March 21, 2022. Over the past three months NeuroSense Therapeutics has seen average daily volume of around 596,090 shares. However, volume of 88.85 million shares or dollar volume of around $527.77 million, has already exchanged hands through early trading.
Shares of NeuroSense Therapeutics are surging after the company announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin pharmacokinetic study of PrimeC in adult patients. PrimeC is a drug candidate that seeks to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that can cause complete paralysis and death in less than five years after being diagnosed.
PrimeC is an orally administered treatment, which is comprised of a fixed-dose combination of ciprofloxacin and celecoxib, two FDA-approved drugs. The drug candidate is formulated to target several key mechanisms of ALS, which has the potential to slow the progress of the neurodegenerative illness.
NeuroSense Therapeutics recently completed its Phase 2a clinical study, which demonstrated PrimeC’s ability to reduce functional and respiratory deterioration related to ALS. The company is planning to launch the Phase 2b clinical study, which will be a double-blind, placebo-controlled and multinational trial, sometime during the second quarter 2022.
“Data from our Phase IIa clinical study confirmed that PrimeC is a novel therapy with the potential to help people with ALS and address a $3 billion market in need of a more effective treatment,” stated NeuroSense CEO Alon Ben-Noon. “As we prepare to initiate our Phase IIb study in the next few months, the goal of our pharmacokinetic study under FDA IND is to generate additional data on the bioavailability of PrimeC as it relates to food intake in healthy individuals. We are deeply committed to improving the lives of people with ALS and are proud to develop a new potential treatment to address this complex disease.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
